The board of directors of Peijia Medical Limited announced that the Company has enrolled the first patient of the multi-center registration clinical trial for TaurusTrio?? transcatheter aortic valve replacement system, the licensed-in TrilogyTM Heart Valve System for aortic regurgitation from JenaValve Technology Inc. The first implant has been successfully completed by Professor Yongjian Wu and Professor Guangyuan Song in Beijing An Zhen Hospital, Capital Medical University on July 26, 2023. The registration clinical trial of the System is a single-arm, prospective, multi-center study.

It is designed to assess the safety and efficacy of the System in treating patients with native symptomatic severe AR, who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. The results of this clinical trial will be included in the Company's future submission of registration application to the National Medical Products Administration (the "NMPA"). In June 2023, the System was formally accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA.

As of the date of this announcement, no transfemoral TAVR product for AR has been approved by the NMPA. Reference is made to the Company's announcement dated January 14, 2022. The Group obtained an exclusive license from JenaValve for developing, manufacturing and commercializing Trilogy??

Heart Valve System in the Greater China region. Reference is also made to the Company's announcement date May 15, 2023. On May 12, 2023, the successful completion of the first two commercial implants with the Trilogy??

Heart Valve System took place in Hong Kong. The Company may not be ABLE to ULTIMATically DEVELOP and market TaurusTrio?? TAVR system SUCCESSF fully.

ShareHOLDers of the Company and POTENTIAL INVESTORS are ADVISED to EXERCISE DUE care when DEALING in the shares of the Company.